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A novel high-performance liquid chromatography-diode array detectionmethod based onmicroextraction
by packed sorbent (MEPS) as a sample preparation approach is described for the determination of
zonisamide (ZNS) in human plasma. MEPS parameters were optimised using a Plackett–Burman
experimental design to achieve the best extraction conditions. The chromatographic separation of ZNS
and chloramphenicol [internal standard (IS)] was achieved in less than 5 min on a C18-column, at 35 C,
using a mobile phase composed of acetonitrile/water (35 : 65, v/v) pumped isocratically at 1.0 mL min1.
ZNS and IS were detected at 240 nm. No endogenous and exogenous interference was observed at the
retention times of the analyte of interest (ZNS) and IS. A good linearity was obtained for ZNS (r2 ¼
0.9960) in the range of 0.2–80 mg mL1 in plasma. The method was shown to be precise (CV # 13.3%)
and accurate (bias 12.3%), and the absolute recovery ranged from 63.8% to 65.2%. The stability of ZNS
was demonstrated in plasma samples under all predictable handling and storage conditions. The
proposed assay was applied to the analysis of human plasma samples obtained from epilepsy patients
under ZNS therapy, and the results supported its usefulness for therapeutic drug monitoring in clinical
practice.
1. Introduction
Zonisamide (ZNS), chemically known as 1,2-benzisoxazole-3-
methanesulfonamide,1,2 is an antiepileptic drug licensed in the
European Union for monotherapy or adjunctive therapy of
partial seizures with or without generalisation.1,3 It is charac-
terised by unique structural, mechanistic and pharmacokinetic
properties that are distinct from those of other antiepileptic
drugs.4 The mechanism of action described involves the
blockage of voltage-dependent sodium and T-type calcium
channels interrupting synchronised neuronal ring, thereby
preventing the spread of seizure activity and reducing the
recurrence of epileptic seizures.3,5,6 In addition, this drug also
has some effects on the synthesis, release and degradation of
a number of different neurotransmitters, including glutamate,
g-aminobutyric acid, dopamine, serotonin and acetylcholine,
which may lead to an increase in inhibitory synaptic
neurotransmission.3,6–8
Regarding the pharmacokinetic properties, ZNS is rapidly
absorbed from the gastrointestinal tract and presents a high
oral bioavailability.2,3,7 It binds moderately to human serum
albumin (about 50%), but tends to accumulate in red blood
cells.3,9 In addition, ZNS is partially metabolised in the liver
through cytochrome P450 3A4 (under reductive cleavage) and,
subsequently, it is eliminated through the renal route.2,9 The
favourable pharmacokinetic prole of ZNS supports its
increasing use. Moreover, it has the advantage of not modifying
signicantly the plasmatic levels of other antiepileptic drugs
administered concomitantly.3,7
A therapeutic reference range of 10–40 mg mL1 for ZNS has
been proposed for appropriate seizure management.10–12 In fact,
the implementation of therapeutic drug monitoring of ZNS in
routine clinical practice requires the availability of suitable
bioanalytical methodologies to measure ZNS concentration
levels in biological samples in order to adjust the patient's
medication regimen and achieve optimal therapeutic outcomes.
In this sense, several techniques have been developed and
validated to quantify ZNS in human matrices (e.g. serum,
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